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Abstract
Aim: To assess the clinical trial and real-world data for adjunctive perampanel in
adolescents and develop consensus recommendations to guide the use of peram-
panel in this population in clinical practice. Methods: In May 2015, 15 epilepsy
experts attended a Consensus Development Meeting to assess the clinical trial
data for perampanel, specific to the adolescent age group (12-17 years) and
develop consensus treatment recommendations. Results and Discussion: Analysis
of the adolescent subgroup data of three pivotal placebo-controlled, double-blind,
phase 3 trials investigating perampanel in patients with ongoing focal epileptic
seizures despite receiving one to three antiepileptic drugs found that perampanel
4–12 mg was superior to placebo. The tolerability profile of perampanel was gen-
erally acceptable. Adolescent patients receiving long-term treatment with peram-
panel in an open-label extension study maintained improvements in seizure
control compared with baseline, with a favorable risk-benefit profile. A phase 2
study showed that perampanel had no clinically important effects on cognitive
function, growth, and development. Conclusion: Perampanel is a welcome addi-
tion to the armamentarium of existing antiepileptic drugs as it represents a new
approach in the management of epilepsy, with a novel mechanism of action, and
the potential to have a considerable impact on the treatment of adolescents with
epilepsy.
Introduction
Glutamate is the mediator of most fast excitatory neuro-
transmission in the central nervous system. There are
three classes of ionotropic receptors, each with distinct
physiological roles that mediate glutamate’s fast excitatory
neurotransmission at the synapses: a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-
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d-aspartate (NMDA), and kainate receptors (Rogawski
2011). AMPA receptors are distributed throughout the
brain and they are particularly prominently expressed in
areas relevant to epilepsy, including the hippocampus and
amygdala. These receptors form an integral part of every
network in the brain that requires synaptic transmission
by glutamate. The AMPA receptors play a fundamental
role in fast excitatory synaptic transmission, and therefore
are considered to be more relevant as a therapeutic target
than NMDA and kainate receptors (Rogawski 2011). Per-
ampanel (Fycompa, Eisai Co., Ltd, Tokyo, Japan) was
developed specifically to target AMPA receptors. Peram-
panel is a potent, orally active, noncompetitive, highly
selective ionotropic AMPA glutamate receptor antagonist
indicated for the treatment of partial-onset seizures with
or without secondarily generalized seizures (Hanada et al.
2011) in patients with epilepsy aged 12 years and older.
Perampanel is approved in more than 45 countries,
including the USA and in the EU, for adjunctive treatment
of partial seizures with or without secondarily generalized
seizures in patients with epilepsy aged ≥12 years of age.
Methods
In May 2015, a panel of epilepsy experts from Asia met
in Taipei, Taiwan, to discuss the clinical trial data for per-
ampanel specific to the adolescent age group (12‒
17 years). The objectives of this panel were to develop
consensus treatment recommendations for perampanel
use in adolescent patients based on evidence from the
published literature, clinical trial experience, and practical
experience in routine clinical practice, and to provide
clinical recommendations for use in real-world settings.
The recommendations made are based on the published
literature and clinical trial, and real-world experience;
consensus was reached after discussion within the group
of epilepsy experts. The aim of the report is to provide an
up-to-date overview of clinical trial data for perampanel
in adolescents, including treatment recommendations,
data gaps, and future directions, to guide the use of per-
ampanel in the adolescent population with epilepsy.
Discussion
Mechanism of action of perampanel
Perampanel selectively inhibits AMPA-induced calcium
influx, thus reducing neuronal excitation (Rogawski
2011). Although perampanel is highly selective for AMPA
receptors, it also has a weak effect on kainate receptors,
but has not been found to interact with other molecular
targets, including NMDA receptors, at relevant concentra-
tions. In cultured rat cortical neurons, perampanel acts in
a concentration-dependent manner, with a 50% inhibitory
concentration of 93 nM compared with 12.5 lM for the
noncompetitive AMPA receptor antagonist GYKI52466
(Hanada et al. 2011). AMPA receptor antagonists have a
broad spectrum of anticonvulsant activity, being effective
against fully kindled seizures (Rogawski 2011).
Randomized clinical trials
Three multinational, multicenter, double-blind, random-
ized, placebo-controlled, phase 3 trials (studies 304
[NCT00699972] (French et al. 2012), 305 [NCT00699582]
(French et al. 2013) and 306 [NCT00700310] (Krauss
et al. 2012); Fig. 1), comprising a study population of
adults and adolescents (age 12–17 years) were done to
establish the minimum effective dose and the dose range
(2–12 mg) of once-daily perampanel. Patients with
Figure 1. Design overview of three randomized controlled phase 3 trials and an open-label extension study of perampanel. AED, antiepileptic drug;
MTD, maximum tolerated dose. *Studies 304 (French et al. 2012), 305 (French et al. 2013), and 306 (Krauss et al. 2012). †Study 307 (Krauss et al. 2013).
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refractory epilepsy who were taking one to three approved
antiepileptic drugs (AEDs) at baseline, but were still hav-
ing uncontrolled partial-onset seizures were enrolled.
Study 306 assessed the low to middle dose range (2, 4,
and 8 mg) (Krauss et al. 2012). The two other trials,
studies 304 and 305, had identical methodology and
assessed the higher daily doses of 8 and 12 mg (French
et al. 2012, 2013). Study 307 (NCT00735397) was an
open-label extension study of patients completing the
double-blind phase of the three pivotal phase 3 trials
(Krauss et al. 2013). Another recent placebo-controlled
phase 2 study was designed to determine the effect of per-
ampanel on cognition, growth, safety, tolerability, and
pharmacokinetics (PK) in adolescents (study 235;
NCT01161524; Fig. 2; Hussein et al. 2015; Pina-Garza
et al. 2015; Renfroe et al. 2015). An observational retro-
spective multicenter survey provided real-world clinical
data on the effectiveness and tolerability of perampanel in
children and adolescents (age 2–17 years) with refractory
epilepsy (Biro et al. 2015).
Consensus statement 1
Perampanel has a novel mechanism of action. AMPA
receptors are of primary importance based on a rational
hypothesis of seizure initiation and spread. This novel
mechanism of action can be considered as a rational com-
bination therapy in patients with partial-onset seizures
who have failed to gain control with other AEDs.
Efficacy and safety of perampanel in
adolescents
In a pooled analysis of the three randomized, controlled,
phase 3 trials (studies 304, 305, and 306) (French et al.
2012, 2013; Krauss et al. 2012), primary efficacy end-
points were median percentage change in frequency of all
partial seizures per 28 days (baseline vs. double-blind
phase) and percentage of patients achieving a ≥ 50%
reduction in the frequency of all partial seizures per
28 days (50% responder rate; baseline vs. maintenance
phase). The median percentage changes in the frequencies
of complex partial seizures plus secondarily generalized
seizures and secondarily generalized seizures only were
assessed as secondary and exploratory endpoints, respec-
tively (Steinhoff et al. 2013).
A total of 1480 patients were enrolled in studies 304,
305, and 306 (French et al. 2012, 2013; Krauss et al.
2012). Of these, 145 adolescent patients were randomized
to adjunctive therapy with either perampanel (n = 100)
Figure 2. Design of a phase 2 study of perampanel (study 235) (Hussein et al. 2015; Pina-Garza et al. 2015; Renfroe et al. 2015). R,
randomization. 1All patients were retained to the last visit of extension part A. 2Part B was optional (a patient proceeded to or completed part B
if perampanel was not commercially available or extended-access program 401 was not in place in their country of residence). 3Follow-up was
conducted for all patients 4 weeks after their last on-treatment visit.
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or placebo (n = 45); 143 received ≥1 dose of study drug
and were included in the analysis. In the three studies,
79% of patients receiving perampanel and 89% of those
receiving placebo were taking two or three baseline AEDs.
The pooled data from the three trials show that, in per-
ampanel-treated adolescents, efficacy outcomes for the
adolescent age group (12–17 years) were consistent with
the overall findings of the phase 3 studies (French et al.
2012, 2013; Krauss et al. 2012). Seizure frequency and
responder rate data supported an effective dose range of
perampanel, 4–12 mg in adolescent patients, providing
seizure reduction in patients with refractory partial-onset
seizures (Fig. 3).
Among adolescents, the PK profile of perampanel was
consistent across age groups and did not vary by any
demographics. The predicted probability of response
increased with perampanel exposure. Between baseline
and end of treatment, perampanel was not associated with
any clinically significant changes in mean hematology and
clinical chemistry values, vital signs, mean electrocardio-
gram parameters or skin photosensitivity (Rosenfeld et al.
2015). Perampanel demonstrated a favorable risk–-benefit
profile. The most common (observed in ≥5% of patients)
treatment-emergent adverse events (TEAEs) were dizzi-
ness, somnolence, aggression, decreased appetite, and
rhinitis (Rosenfeld et al. 2015). Of note was the incidence
of aggression, which was higher in patients treated with
perampanel (n = 8) than with placebo (n = 0). The inci-
dence of aggression in adolescents was also higher than
that observed in adults aged 18–65 years (8% vs. 1%). Of
the eight adolescents who experienced aggression, two
experienced serious aggression-related AEs (both male
patients: one receiving 2 mg and the other receiving
12 mg) and four required drug interruption or adjust-
ment; the patient randomized to the 12 mg group discon-
tinued treatment. The AEs were described as aggressive
behavior, temper tantrums, behavioral aggression, or
increased aggressive behavior.
Consensus statement 2
Adolescent subgroups display similar outcome tendencies
to the overall study group (no significant differences
between the adult and adolescent groups). Adjunctive
Figure 3. Pooled efficacy data from pivotal phase 3 studies 304 (French et al. 2012), 305 (French et al. 2013), and 306 (Krauss et al. 2012).
(A) Median percentage change in seizure frequency per 28 days of treatment versus baseline; (B) 50% responder rates; and (C) median
percentage change for complex partial seizures plus secondarily generalized seizures (Steinhoff et al. 2013). The subanalysis was not powered for
statistical analysis.
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perampanel treatment in adolescents produced better sei-
zure control than placebo and sustained seizure frequency
improvements for up to 2 years of follow-up. Patients with
secondarily generalized seizures achieved greater seizure
freedom. Adjunctive perampanel in this group had a gen-
erally favorable tolerability profile. There could be a slight
increase in aggression in the adolescent patient group.
In the observational real-world study of 58 patients
(mean age, 10.5 years; range, 2–17 years) with various
refractory epilepsies, 18 patients achieved ≥50% seizure
reduction for a response rate of 31% after 3 months (Biro
et al. 2015). Five patients (9%) achieved complete seizure
control and five patients (9%) experienced aggravation of
seizures. The most frequent AEs were reduced vigilance
or fatigue (28%) and behavioral changes (24%).
Long-term results
In the open-label extension study 307, long-term safety
and tolerability of perampanel as an adjunctive treatment
for refractory partial-onset seizures was evaluated. In
addition, the maintenance effect of perampanel for treat-
ment of refractory partial-onset seizures was assessed
(Krauss et al. 2013). Of 129 adolescent patients complet-
ing the pivotal phase 3 studies, 124 enrolled in the
extension study; 122 patients were included in the inten-
tion-to-treat analysis set and 121 in the safety analysis set.
In this study, 82% of patients in the safety analysis set
were taking two or three AEDs.
Interim results from this trial showed that, adolescent
patients receiving long-term treatment with perampanel
maintained improvements in seizure control compared
with baseline. The decrease in seizure frequency was con-
sistent and maintained in those patients over at least 1 year
of perampanel exposure (Fig. 4) (Renfroe et al. 2014).
Consistent with the pivotal phase 3 trials (French et al.
2012, 2013; Krauss et al. 2012), perampanel had a favor-
able tolerability profile in adolescent patients with refrac-
tory partial-onset seizures over the longer term. The most
common treatment-related TEAEs requiring perampanel
interruption or dose adjustment were dizziness (13.2%,
n=16), somnolence (11.6%, n=14), aggression (6.6%,
n=8), irritability (2.5%, n=3), asthenia, ataxia, convulsion,
and abnormal behaviour(n=2;1.7% for each) (Steinhoff
et al. 2013). The discontinuation rate due to TEAEs was
14.9% (n=18) and the rate of serious AEs in extension
study was 14.0% (n=17). Behavioral TEAEs noted during
the extension study included aggression (18.2% n=22),
insomnia (6.6% n=8), abnormal behavior (4.1% n=6),
anxiety (4.1% n=5), and anger (3.3% n=4). Of the 22
patients experiencing aggression, 21 were receiving higher
dose of perampanel, 8–12 mg. A higher incidence of
aggression was observed among adolescents compared with
adults. However, most cases were mild or moderate (mild
[n = 9], moderate [n = 10], severe [n = 3]); three patients
with aggression discontinued the study (Steinhoff et al.
2013). Adolescent patients treated with perampanel and
their caregivers need to be aware of the potential for
aggressive behavior, especially during titration (Rosenfeld
et al. 2015). If aggression is noted, a trial of alternate day
dosing could be considered (Marina Nikanorova, Danish
Epilepsy Centre Filadelfia, pers. Comm. 2015). Overall,
perampanel demonstrated a favorable risk–-benefit profile.
Consensus statement 3
Patients receiving perampanel should be monitored for
AEs related to irritability and aggression, particularly
Figure 4. Responder rates in the open-
label extension study 307 (Krauss et al.
2013; Rosenfeld et al. 2015). CP, complex
partial; SG, secondarily generalized.
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during dose titration and at higher doses. Patients and
caregivers should be counseled regarding the potential
risk of psychiatric or behavioral AEs. Any prior history
of psychiatric or behavioral disorders, family history of
psychiatric disorders, or history of aggression with prior
AEDs should be noted, and slower dose titration and
closer monitoring could be considered. There is no
clear mechanism or hypothesis for aggression. Young
adults are in the process of development, and hence
could be more sensitive to drug-induced aggressive
behavior.
Effect of perampanel on cognition, growth,
and development
Study 235 was conducted to compare the short-term
effect on cognition of adjuvant perampanel versus placebo
in 133 adolescents with inadequately controlled partial-
onset seizures using the Cognitive Drug Research (CDR)
System Global Cognition Score (Hussein et al. 2015;
Pina-Garza et al. 2015; Renfroe et al. 2015; Meador et al.
2016). The primary outcome measure was change from
baseline (week 0) to end of maintenance therapy (week
19) in global cognition score. Key secondary outcome
measures were change from baseline in five CDR System
cognitive domains of: power of attention; continuity of
attention; quality of episodic memory; quality of working
memory; and speed of memory.
Data from this trial showed that adjunctive therapy
with perampanel up to 12 mg/day was associated with
improved seizure control and was well tolerated in ado-
lescents with inadequately controlled partial seizures
(Renfroe et al. 2015). Patients who received perampanel
reported a higher incidence of aggression and irritability
compared with placebo in this study. However, these
findings are consistent with adolescent data from the
phase 3 studies (French et al. 2012, 2013; Krauss et al.
2012).
Consensus statement 4
The once-daily night-time dosing, simple titration sched-
ule, and long half-life may offer ease of use and potential
for adherence in the adolescent group. The advantages of
once-daily night-time dosing include the potential for a
more stable mean drug concentration over time,
improved tolerability profile, maximal use of the thera-
peutic window, and the possibility to achieve better sei-
zure control. Improvements in overall treatment
effectiveness may therefore increase adherence in adoles-
cent patients and the long half-life may offer additional
protection against lack of adherence in case of a missed
dose. Careful and slow titration over 2–4 weeks in adoles-
cent patients is recommended.
Mean change in CDR System Global Cognition Score
from baseline showed that perampanel did not signifi-
cantly influence cognitive characteristics (P = 0.145;
Table 1; Meador et al. 2016). No significant differences
were observed with change from baseline in Power of
Attention (P = 0.219) and Quality of Working Memory
(P = 0.579). There were small, but significant, differences
in favor of placebo for Continuity of Attention
(P = 0.013) and Speed of Memory (P = 0.032), while
Quality of Episodic Memory (P = 0.012) was improved
in patients receiving perampanel (Table 1).
The most commonly reported TEAEs for perampanel-
treated patients were dizziness and somnolence. Aggres-
sion was reported in 2.1% of placebo-treated patients and
8.2% of perampanel-treated patients. Three of seven per-
ampanel-treated patients with aggression required dose
modification and two had serious aggression, although
none required treatment discontinuation.
Perampanel steady state exposure studies indicated no
effect of exposure to perampanel on CDR System Global
Cognition Score, Quality of Working Memory, and Speed
of Memory (Hussein et al. 2015). PK–pharmacodynamic
(PD) relationships were apparent for Power of Attention
Table 1. Effect of perampanel on cognitive function assessed by CDR System Global Cognition Score in study 235 – full analysis (Meador et al.
2016).
Parameter
LS mean change (SE)
Difference in LS means (95% CI)
P-valuePlacebo (n = 44) Perampanel (n = 79) Perampanel versus placebo
CDR System Global Cognition Score 1.6 (1.3) 0.6 (1.0) 2.2 (5.2 to 0.8) 0.145
Power of attention 2.7 (3.0) 6.9 (2.3) 4.2 (11.0 to 2.6) 0.219
Quality of working memory 2.0 (1.5) 1.1 (1.2) 1.0 (4.4 to 2.5) 0.579
Continuity of attention 1.6 (1.2) 1.7 (0.9) 3.3 (6.0 to 0.7) 0.013
Quality of episodic memory 1.2 (1.5) 3.0 (1.1) 4.2 (0.9 to 7.5) 0.012
Speed of memory 7.0 (2.7) 0.3 (2.1) 6.6 (12.7 to 0.6) 0.032
SE, standard error; CI, confidence interval; LS, least squares.
Statistical significance – (P < 0.05).
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(beneficial), Continuity of Attention (worsening), and
Quality of Episodic Memory (beneficial). These findings
were further supported by PK–PD analyses using
nonlinear mixed effects modeling.
Consensus statement 5
No negative effect of perampanel exposure on the pri-
mary study outcome measure of CDR System Global
Cognition Score was observed. This substantiates the pri-
mary study endpoint results that there is no evidence of
an overall short term effect of perampanel on cognitive
function, as measured by CDR System Global Cognition
Score, when compared with placebo.
Overall, perampanel did not negatively impact growth
and development compared with placebo (Pina-Garza
et al. 2015). Mean change in weight percentile decreased
slightly for placebo (baseline (49.9%) to end of treatment
(49.1%), 1.0; standard deviation [SD]: 4.9) and increased
slightly for perampanel (baseline (46.1%) to end of treat-
ment (48.0%), 1.9; SD: 6.7). Mean change in height per-
centile was similar for both the placebo (baseline (47.5%)
to end of treatment (47.7%), 0.7; SD: 8.2) and peram-
panel groups (baseline [44.1%] to end of treatment
[43.4%], 0.8; SD: 5.9; Fig. 5). The sex- and age-specific
percentiles for weight and height were calculated from the
Centers for Disease Control and Prevention Growth Charts
(Centers for Disease Control and Prevention). Insulin-like
growth factor-1 (IGF-1) decreased minimally with peram-
panel treatment (1.1; SD: 113.9) and to a greater extent
with placebo treatment (13.9; SD: 93.9). There were min-
imal or no changes from baseline for thyrotropin, free thy-
roxin, and free triiodothyronine, with no difference
between treatment groups. There were no clinically impor-
tant changes in bone age from baseline to the end of treat-
ment. When compared with placebo, perampanel did not
negatively affect sexual development in either males or
females (Tanner staging; Marshall and Tanner 1970).
Consensus statement 6
The average weight change observed in adolescents receiv-
ing perampanel is consistent with that expected for the
general adolescent population and thus can be attributed
to normal adolescent growth rather than a TEAE. Adjunc-
tive perampanel therapy in adolescents with partial sei-
zures showed no overall short-term effects on growth and
development relative to placebo. Long-term effects of
perampanel on cognition, growth and development in
adolescents should be evaluated in future studies.
Consensus statement 7
All adolescent patients with refractory partial-onset sei-
zures should be reviewed by an epilepsy specialist when
possible. Perampanel may be initiated by an epilepsy spe-
cialist, appropriately qualified pediatrician or general neu-
rologist. Perampanel can be considered a second-line
adjunctive therapy option in patients aged 12 years and
older with partial-onset seizures. Perampanel may be
combined with other AEDs with good efficacy outcomes.
A higher dose of perampanel may be required in patients
taking enzyme-inducing AEDs.
Consensus statement 8
Perampanel should be initiated at a dose of 2 mg/day,
taken at night, and titrated by increments of 2 mg every
2–4 weeks according to the clinical need to achieve the
maximum tolerated dose (MTD; up to 12 mg/day). The
administration schedule was established from the results
of the clinical trials with fixed titration schedules but,
based on real-world clinical practice experience, slower
titration rates are recommended for fewer side effects and
better adherence in adolescent patients. Consider with-
drawing perampanel if there is no evidence of clinical
benefit once the MTD has been reached and maintained
Figure 5. Percentile change from baseline in (A) weight and (B) height.
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for an adequate period. Patients with partial-onset sei-
zures with motor symptoms or secondarily generalized
seizures can have greater benefit with perampanel.
Perampanel trial summary
Adjunctive therapy with perampanel (up to 12 mg/day)
resulted in improved seizure control and was well tolerated
in adolescents with inadequately controlled partial seizures.
PK–PD results indicate that perampanel has no clinically
important short term effects on overall cognitive function,
growth and development in adolescents. Results for adoles-
cents were comparable to the overall study population.
However, aggression was more frequent in adolescents
than in adults, in some cases leading to treatment discon-
tinuation.
Future directions
Several data gaps pertinent to perampanel were discussed,
and many opportunities to define the future direction for
optimizing the use of perampanel in the pediatric popula-
tion and adolescents were presented by the meeting atten-
dees. These suggestions are outlined below.
Reasons for the increased occurrence of aggression with
perampanel treatment remain unclear, indicating a need to
understand the underlying mechanism of treatment-related
aggression. This will help optimize treatment in this patient
population. As such, the expert group suggested using post-
marketing surveillance studies to begin understanding
aggression in adolescent patients taking perampanel.
There was agreement that the safety and effectiveness
of perampanel in pediatric patients younger than 12 years
are required to inform drug use in younger patients. This
could be facilitated with the implementation of open-label
studies in this population.
There are data supporting the use of perampanel in dif-
ferent types of epilepsy, including complex partial seizures
and primary generalized tonic–clonic seizures (Steinhoff
et al. 2014). Seizure freedom was achieved in 15% of
patients and the responder rate was 50%. Nonetheless,
robust data specific to adolescents are required as these
are important for pediatricians in clinical practice.
Perampanel offers a potential benefit for the most
refractory patients. Perampanel has low potential for drug
interactions and predictable PK. Good tolerability is
observed in most of the patients when assessing cogni-
tion, mood, and behavior. Long-term effect of peram-
panel on cognition, growth and development in
adolescents should be evaluated in the future studies.
Ease of use in a titration scheme and once-daily formu-
lation offer advantages over other AEDs. Perampanel may
be combined with other AEDs with good efficacy
outcomes. A higher dose of perampanel may be required
in patients taking enzyme-inducing AEDs. It was sug-
gested to explore whether other AEDs can work synergis-
tically with perampanel.
Presence of a comorbidity and quality of life are at least
as important as seizure frequency in patients who are not
seizure free. These data are required to recommend appro-
priate treatment for epilepsy in clinical practice.
Studies are required to evaluate perampanel as a
monotherapy for the treatment of epilepsy. Perampanel
should be evaluated from a pharmacoeconomic point of
view.
In conclusion, perampanel is a welcome addition to the
armamentarium of existing antiepileptic drugs as it repre-
sents a new approach in the management of epilepsy. Per-
ampanel has a novel mechanism of action, and the
potential to have a considerable impact on the treatment
of adolescents with epilepsy. However, further research is
needed to optimize perampanel therapy.
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